Peyronie's disease: perspectives on therapeutic targets

Bibliography

• Shindel AW, Lue TF. Peyronie's disease: past, present, future? Curr Urol Rep 2008;9:425-7
   PubMedGoogle Scholar
• Shahram SG, Nestor FG, Ching-Shwun L, Peyronie's disease:a review. J Urol 2003;169:1234-41
   PubMedGoogle Scholar
• Bivalacqua TJ, Purhoit SK, Hellstrom WJG. Peyronie's disease: advances in basic science and pathophysiology. Curr Urol Rep 2000;1:297-301
   PubMedGoogle Scholar
• Bivalacqua TJ, Diner EK, Novak TE, A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000;163:1992-8
   PubMed Web of Science ®Google Scholar
• Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997;158:1388-90
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Oktar T, Kandirali E, Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction. Int J Impot Res 2004;16:540-3
   PubMedGoogle Scholar
• Kendirci M, Nowfar S, Gur S, The relationship between the type of penile abnormality and penile vascular status in patients with peyronie's disease. J Urol 2005;174:632-5
   PubMedGoogle Scholar
• Deveci S, Palese M, Parker M, Erectile function profiles in men with Peyronie's disease. J Urol 2006;175:1807-11
   PubMedGoogle Scholar
• Vernet D, Nolazco G, Cantini L, Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from Stem Cells: implications for Peyronie's Disease. Biol Reprod 2005;73:1199-210
   PubMed Web of Science ®Google Scholar
• Pryor J, Akkus E, Alter G, Peyronie's disease. J Sex Med 2004;1:110-15
   PubMedGoogle Scholar
• Hauck EW, Diemer T, Schmelz HU, A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006;49:987-97
   PubMedGoogle Scholar
• Deveci S, Hopps CV, O'Brien K, Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007;4:485-90
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Riedner CE, Fuchs S, A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease. J Sex Med 2010;7:1529-37
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Alex B, Choi JM. Predicting delay in presentation in men with Peyronie's disease. J Sex Med 2010;7:2226-30
   PubMed Web of Science ®Google Scholar
• Ralph D, Gonzalez-Cadavid N, Mirone V, The management of Peyronie's disease: Evidence-based 2010 guidelines. J Sex Med 2010;7:2359-74
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9
   PubMed Web of Science ®Google Scholar
• Levine LA. Medical therapy for Peyronie's disease-state of the art 2006. J Sex Med 2007;4(Suppl 1):41
   Google Scholar
• Sasso F, Gulino G, Falabella R, Peyronie's disease: lights and shadows. Urol Int 2007;78:1-9
   PubMedGoogle Scholar
• Kadioglu A, Tefekli A, Erol B. Retrospective review of 307 men with Peyronie's disease. J Urol 2002;168:1075-9
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's Disease. J Urol 2006;175:2115-18
   PubMed Web of Science ®Google Scholar
• Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors, Campbell Walsh-Urology. 9th edition. Saunders Elsevier, Philadelphia, PA; 2007. p. 718-49
   Google Scholar
• Brock G, Hsu GL, Nunes L, The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997;157:276-81
   PubMed Web of Science ®Google Scholar
• Gentile V, Modesti A, La Pera G, Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive dysfunction. J Androl 1996;17:96-103
   PubMedGoogle Scholar
• Udelson D, Nehra A, Hatzichristou DG, Engineering analysis of penile hemodynamic and structural-dynamic relationships: part I – clinical implications of penile tissue mechanical properties. Int J Impot Res 1998;10:15-24
   PubMedGoogle Scholar
• Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997;157:311-15
   PubMed Web of Science ®Google Scholar
• Jordan GH. Peyronie's disease. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors, Campbell-Walsh Urology. 9th edition. Saunders Elsevier, Philadelphia, PA; 2007. p. 818-38
   Google Scholar
• Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie's disease. Ann NY Acad Sci 1949;390:401-52
   Google Scholar
• Yudkin JS. Peyronie's disease in association with metoprolol. Lancet 1977;310:1355
   Google Scholar
• Vande Berg JS, Devine CJ, Horton CE, Mechanisms in calcification in Peyronie's disease. J Urol 1982;127:52-6
   PubMedGoogle Scholar
• Somers KD, Winters PA, Dawson DM. Chromosomal abnormalities in Peyronie's disease. J Urol 1987;137:672-6
   PubMedGoogle Scholar
• Carreri MP, Serraino D, Palmiotto F, A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol 1998;51:511-15
   PubMedGoogle Scholar
• Bjekic MD, Vlajinac HD, Sipetic SB, Risk factors for Peyronie's disease: a case-control study. BJU Int 2006;97:570-4
   PubMed Web of Science ®Google Scholar
• Casabe A, Bechara A, Cheliz G, Risk factors of Peyronie's disease. What does our clinical experience show? J Sex Med 2011;8:518-23
   PubMed Web of Science ®Google Scholar
• Tsafrakidis P, Blake C, Pearcy R, Peyronie's disease. Trend Urol Gynaecol Sex Heal 2009;14:17-21
   Google Scholar
• Nyberg LM, Bias WB, Hochberg MC. Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982;128:48-51
   PubMed Web of Science ®Google Scholar
• Ziegelbaum M, Thomas A Jr, Zachary AA. The association of Peyronie's disease with HLA B7 cross-reactive antigens. A case report of identical twins. Cleve Clin J Med 1987;54:427-30
   PubMedGoogle Scholar
• Rompel R, Weidner W, Mueller-Eckhardt G. HLA association of idiopathic Peyronie's disease: an indication of autoimmune phenomena in etiopathogenesis? Tiss Antig 1991;38:104-6
   PubMed Web of Science ®Google Scholar
• Rompel R, Mueller-Eckhardt G, Schroeder-Printzen I, HLA antigens in Peyronie's disease. Urol Int 1994;52:34-7
   PubMed Web of Science ®Google Scholar
• Nachtsheim DA, Rearden A. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol 1996;156:1330-4
   PubMed Web of Science ®Google Scholar
• Hauck EW, Hauptmann A, Schmelz HU, Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease. J Urol 2003;169:369-72
   PubMedGoogle Scholar
• Qian A, Meals RA, Rajfer J, Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004;64:399-404
   PubMed Web of Science ®Google Scholar
• Leffell MS, Devine CJ Jr, Horton CE, Non-association of Peyronie's disease with HLA B7 cross-reactive antigens. J Urol 1982;127:1223-4
   PubMedGoogle Scholar
• Hauck EW, Hauptmann A, Weidner W, Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie's disease. J Urol 2003;170:1443-6
   PubMedGoogle Scholar
• Devine CJ Jr, Somers KD, Jordan SG, Proposal: trauma as the cause of the Peyronie's lesion. J Urol 1997;157:285-90
   PubMed Web of Science ®Google Scholar
• Zargooshi J. Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma. J Urol 2004;172:186-8
   PubMed Web of Science ®Google Scholar
• Szobota J, Honig S. Local therapy for Peyronie's disease. Curr Sex Heal Rep 2008;5:70-5
   Google Scholar
• Gonzalez -Cadavid NF. Mechanisms of penile fibrosis. J Sex Med 2009;6(Suppl 3):353-62
   PubMedGoogle Scholar
• Davis CJ Jr. The microscopic pathology of Peyronie's disease. J Urol 1997;157:282-4
   PubMedGoogle Scholar
• Magee TR, Qian A, Rajfer J, Gene expression profiles in the Peyronie's disease plaque. Urology 2002;59:451-7
   PubMed Web of Science ®Google Scholar
• Lin CS, Lin G, Wang Z, Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease. Biochem Biophys Res Commun 2002;295:1014-19
   PubMedGoogle Scholar
• Szardening-Kirchner C, Konrad L, Hauck EW, Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease. World J Urol 2009;27:123-30
   PubMedGoogle Scholar
• Haag SM, Hauck EW, Szardening-Kirchner C, Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007;51:255-61
   PubMedGoogle Scholar
• El-Sakka AI, Hassoba HM, Pillarisetty RJ, Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. Urol 1997;158:1391-4
   Google Scholar
• Lin GT, Wang Z, Liu BC, Identification of potential biomarkers of Peyronie's disease. Asian J Androl 2005;7:237-43
   PubMedGoogle Scholar
• De Young LX, Bella AJ, O'Gorman DB, Protein biomarker analysis of primary Peyronie's disease cells. J Sex Med 2010;7:99-106
   PubMed Web of Science ®Google Scholar
• Haag SM, Hauck EW, Eickelberg O, Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie's disease. Eur Urol 2008;53:425-31
   PubMedGoogle Scholar
• El-Sakka AI, Hassa MU, Nuners L, Histological and ultrastructural alteration in an animal model of Peyronie's disease. Br J Urol 1998;81:445-52
   PubMedGoogle Scholar
• El-Sakka AI, Hassoba HM, Chui RM, An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997;158:2284-90
   PubMed Web of Science ®Google Scholar
• Bivalacqua TJ, Diner EK, Novak TE, A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000;163:1992-8
   PubMed Web of Science ®Google Scholar
• Piao S, Ryu JK, Shin HY, Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease. Int J Androl 2008;31:346-53
   PubMedGoogle Scholar
• Davila HH, Ferrini MG, Rajfer J, Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 2003;91:830-8
   PubMed Web of Science ®Google Scholar
• Lucattelli M, Lunghi B, Fineschi S, A new mouse model of Peyronie's disease: an increased expression of hypoxia-inducible factor-1 target genes during the development of penile changes. Int J Biochem Cell Biol 2008;40:2638-48
   PubMed Web of Science ®Google Scholar
• Harrington DJ. Bacterial collagenases and collagen-degrading enzymes and their potential role in human disease. Infect Immun 1996;64:1885-91
   PubMed Web of Science ®Google Scholar
• Chung L, Dinakarpandian D, Yoshida N, Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J 2004;23:3020-30
   PubMed Web of Science ®Google Scholar
• Tallant C, Marrero A, Gomis-Ruth FX. Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta 2010;1803:20-8
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516
   PubMed Web of Science ®Google Scholar
• Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54
   PubMed Web of Science ®Google Scholar
• Lopez B, Gonzalez A, Diez J. Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens 2004;13:197-204
   PubMed Web of Science ®Google Scholar
• Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008;179:2447-55
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Experimental models for the study of the cellular and molecular pathophysiology of Peyronie's disease. In: Levine LA, editor, Current Clinical Urology, Peyronie's Disease: a guide to clinical management. Humana Press, Inc., Totowa, NJ; 2006. p. 19-38
   Google Scholar
• Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001;20:499-508
   PubMed Web of Science ®Google Scholar
• Lamprakopoulos A, Zorzos I, Lykourinas M. The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease. Scand J Urol Nephrol 2000;34:355-60
   PubMed Web of Science ®Google Scholar
• Faurya G, Verdettia J, Fulop T, The elastin–laminin receptor-mediated matrix degradation. Effect of glucose concentration. Role in atherosclerosis. Int Congress Ser 2004;1262:411-13
   Google Scholar
• Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982;10:135-40
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985;134:280-3
   PubMed Web of Science ®Google Scholar
• Gelbard MK, James K, Riach P, Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993;149:56-8
   PubMed Web of Science ®Google Scholar
• Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008;5:180-7
   PubMed Web of Science ®Google Scholar
• Jung H, Winter H. Considerations for the use of clostridial collagenase in clinical Practice. Clin Drug Invest 1998;15:245-52
   Web of Science ®Google Scholar
• Ranzati C, Zahn W, Thom H. Bacterial collagenase and collagen breakdown products exert chemotactic effects in vitro: implication for wound debridement and wound healing. Wound Rep Reg 1994;2:222
   Google Scholar
• Cortivo R, Radice M, Brun P, Biological activity of human collagen breakdown products on fibroblasts. Wounds 1995;7(Suppl A):38A-44A
   Google Scholar
• Gross J. How tadpoles lose their tails: path to discovery of the first matrix metalloproteinase. Matrix Biol 2004;23:3-13
   PubMed Web of Science ®Google Scholar
• Ducka P, Eckhard U, Schonauer E, A universal strategy for high-yield production of soluble and functional clostridial collagenases in E. coli. Appl Microbiol Biotechnol 2009;83:1055-65
   PubMed Web of Science ®Google Scholar
• Mancoll JS, Zhao J, McCauley RL, The inhibitory effect of tamoxifen on keloid fibroblasts. Surg Forum 1996;47:718-20
   Google Scholar
• Mikulec AA, Hanasono MM, Lum J, Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 2001;3:111-14
   PubMedGoogle Scholar
• Entzian P, Schlaak M, Seitzer U, Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997;175:41-51
   PubMed Web of Science ®Google Scholar
• Anderson MS, Shankey TV, Lubrano T, Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000;12(Suppl 3):S25-31
   Google Scholar
• El-Sakka AI, Bakircioglu ME, Bhatnagar RS, The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol 1999;161:1980-3
   PubMed Web of Science ®Google Scholar
• Zarafonetis CJ, Horrax TM. Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA). J Urol 1959;81:770-2
   PubMed Web of Science ®Google Scholar
• Priestley GC, Brown JC. Effects of potassium para-aminobenzoate on growth and macromolecule synthesis in fibroblasts cultured from normal and sclerodermatous human skin, and rheumatoid synovial cells. J Invest Dermatol 1979;72:161-4
   PubMed Web of Science ®Google Scholar
• Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990;49:463-6
   PubMed Web of Science ®Google Scholar
• Roth M, Eickelberg O, Kohler E, Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996;93:5478-82
   PubMed Web of Science ®Google Scholar
• Lin G, Shindel AW, Banie L, Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010;7:1787-97
   PubMed Web of Science ®Google Scholar
• Shindel AW, Lin G, Ning H, Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 2010;7:2077-85
   PubMed Web of Science ®Google Scholar
• Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991;25:89-94
   PubMed Web of Science ®Google Scholar
• Levine LA, Elterman L. Peyronie's disease and its medical management. In: Hellstrom WJ, editor, Male Infertility and Sexual Dysfunction. Springer-Verlag, New York; 1997. p. 474-80
   Google Scholar
• Piao S, Choi MJ, Tumurbaatar M, Transforming growth factor (TGF)-beta type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-beta1 responses in fibroblasts derived from Peyronie's plaque. J Sex Med 2010;7:3385-95
   PubMed Web of Science ®Google Scholar
• Cantini LP, Ferrini MG, Vernet D, Profibrotic role of myostatin in Peyronie's disease. J Sex Med 2008;5:1607-22
   PubMed Web of Science ®Google Scholar
• Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-6
   PubMed Web of Science ®Google Scholar
• Teloken C, Rhoden EL, Grazziotin TM, Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double blind, placebo-controlled study. Int J Impot Res 2004;16:238-43
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Asgari MA, Hosseini SY, A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int 2010;106:240-8
   PubMed Web of Science ®Google Scholar
• Levine LA, Goldman KE, Greenfeld GM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002;168:621-5
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Kendirci M, Matern R, Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006;176:394-8
   PubMed Web of Science ®Google Scholar
• Shirazi M, Haghpanah AR, Badiee M, Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009;41:467-71
   PubMed Web of Science ®Google Scholar
• Inal T, Tokatli Z, Akand M, Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology 2006;67:1038-42
   PubMed Web of Science ®Google Scholar
• Kagan HM. Intra- and extracellular enzymes of collagen biosynthesis as biological and chemical targets in the control of fibrosis. Acta Trop 2000;77:147-52
   PubMed Web of Science ®Google Scholar
• Fish PV, Allan GA, Bailey S, Potent and selective nonpeptidic inhibitors of procollagen C-proteinase. J Med Chem 2007;50:3442-56
   PubMed Web of Science ®Google Scholar
• Bailey S, Fish PV, Billotte S, Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. Bioorg Med Chem Lett 2008;18:6562-7
   PubMedGoogle Scholar
• Trackman PC. Diverse biological functions of extracellular collagen processing enzymes. J Cell Biochem 2005;96:927-37
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol 2010;7:215-22
   PubMed Web of Science ®Google Scholar
• Dunkern TR, Feurstein D, Rossi GA, Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 2007;572:12-22
   PubMed Web of Science ®Google Scholar
• Wang-Rosenke Y, Neumayer HH, Peters H. No signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target. Curr Med Chem 2008;15:1396-406
   PubMedGoogle Scholar
• Sawada N, Itoh H, Miyashita K, Cyclic GMP kinase and RhoA Ser188 phosphorylation integrate pro- and antifibrotic signals in blood vessels. Mol Cell Biol 2009;29:6018-32
   PubMedGoogle Scholar
• Valente EG, Vernet D, Ferrini MG, L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003;9:229-44
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Kovanecz I, Nolazco G, Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006;97:625-33
   PubMed Web of Science ®Google Scholar
• Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol 2006;3:111-15
   PubMedGoogle Scholar
• Ferrini MG, Davila HH, Kovanecz I, Long-term continuous treatment with vardenafil prevents fibrosis and preserves smooth muscle content in the rat corpora cavernosa after bilateral cavernosal nerve transection. Urology 2006;68:429-35
   PubMed Web of Science ®Google Scholar
• Ferrini MG, Kovanecz I, Sanchez S, Long-term continuous treatment with sildenafil ameliorates aging related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007;76:915-23
   PubMed Web of Science ®Google Scholar
• Kovanecz I, Rambhatla A, Ferrini MG, Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction (CvOD) that occurs following cavernosal nerve resection in the rat. BJU Int 2008;101:203-10
   PubMed Web of Science ®Google Scholar
• Iacono F, Prezioso D, Somma P, Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. Urol Int 2008;80:249-52
   PubMedGoogle Scholar
• Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Na Rev Urol 2009;6:415-27
   PubMed Web of Science ®Google Scholar
• Togo S, Liu X, Wang X, PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-beta1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol 2009;296:L959-69
   Google Scholar
• Chung E, Brock G. The role of PDE5 inhibitor in septal scar remodeling: assessment of the clinical and radiological outcomes. J Sex Med 2011;8(Suppl 1):20-1
   Google Scholar
• Ferrini MG, Vernet D, Magee TR, Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002;6:283-94
   PubMed Web of Science ®Google Scholar
• Davila HH, Magee TR, Vernet D, Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol Reprod 2004;71:1568-77
   PubMed Web of Science ®Google Scholar
• Riedl CR, Sternig P, Galle G, Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005;48:656-61
   PubMed Web of Science ®Google Scholar
• Vernet D, Ferrini MG, Valente E, Effect of nitric oxide on fibroblast differentiation into myofibroblasts in cell cultures from the Peyronie's fibrotic plaque and in its rat model in vivo. Nitric Oxide 2002;7:262-76
   PubMed Web of Science ®Google Scholar
• Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol 1983;9:41-5
   Google Scholar
• Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study. Int J Impot Res 2010;22:298-309
   PubMedGoogle Scholar
• Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007;178:1398-403
   PubMed Web of Science ®Google Scholar
• Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001;88:63-7
   PubMed Web of Science ®Google Scholar
• Cavallini G, Biagiotti G, Koverech A, Oral propionyl-lcarnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002;89:895-900
   PubMed Web of Science ®Google Scholar
• Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003;91:522-4
   PubMed Web of Science ®Google Scholar
• Cakan M, Demirel F, Aldemir M, Does smoking change the efficacy of combination therapy with vitamin E and colchicines in patients with early-stage Peyronie's disease? Arch Androl 2006;52:21-7
   PubMedGoogle Scholar
• Lonn E, Bosch J, Yusuf S, Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338-47
   PubMed Web of Science ®Google Scholar
• Bafana A, Dutt S, Kumar A, The basic and applied aspects of superoxide dismutase. J Mol Catalysis B 2011;68:129-38
   Google Scholar
• Ratnam DV, Ankola DD, Bhardwaj V, Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Release 2006;113:189-207
   PubMed Web of Science ®Google Scholar
• Perl M, Chung CS, Ayala A. Apoptosis. Crit Care Med 2005;33(Suppl 12):S526-9
   Google Scholar
• Hall PA, Coates PJ, Ansari B, Regulation of cell number in the mammalian gastrointestinal tract; the importance of apoptosis. J Cell Sci 1994;107:3569-77
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495-516
   PubMed Web of Science ®Google Scholar
• Morishima NNK, Takenouchi H, Shibata T, An endoplasmic reticulum stress-specific caspase cascade in apoptosis. J Biol Chem 2002;277:34287-94
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Nicholson B, Pierpaoli S, Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie's disease. Int J Impot Res 2004;16:288-93
   PubMedGoogle Scholar
• Mulhall JP, Barnas J, Kobylarz K, p53-Associated Parkin-like cytoplasmic protein (Parc) short-interfering RNA (siRNA) alters p53 location and biology of Peyronie's disease fibroblasts. BJU Int 2010;106:1706-13
   PubMedGoogle Scholar
• Mulhall JP, Anderson MS, Lubrano T, Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002;14:397-405
   PubMed Web of Science ®Google Scholar
• Nikolaev AY, Gu W. PARC: a potential target for cancer therapy. Cell Cycle 2003;2:169-71
   PubMedGoogle Scholar
• Loreto C, Barbagli G, Djinovic R, Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptor (DR5) in Peyronie's disease. A biomolecular study of apoptosis activation. J Sex Med 2011;8:109-15
   PubMed Web of Science ®Google Scholar
• Storey S. Targeting apoptosis: selected anticancer strategies. Nat Rev Drug Discov 2008;7:971-2
   PubMed Web of Science ®Google Scholar
• Andresen R, Wegner HE, Banzer D, Ultrasound and soft-tissue radiography to monitor local interferon-alpha2B treatment in Peyronie's disease. Acta Radiol 1996;37:352-6
   PubMedGoogle Scholar
• Hauck EW, Hackstein N, Vosshenrich R, Diagnostic value of magnetic resonance imaging in Peyronie's disease–a comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol 2003;43:293-9
   PubMedGoogle Scholar
• Nolazco G, Kovanecz I, Vernet D, Effect of muscle derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int 2008;101:1156-64
   PubMed Web of Science ®Google Scholar
• Ortiz L, Gambelli F, McBride C, Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407-11
   PubMed Web of Science ®Google Scholar
• Rojas M, Xu J, Woods C, Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005;33:145-52
   PubMed Web of Science ®Google Scholar
• Novo E, Marra F, Zamara E, Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006;55:1174-82
   PubMed Web of Science ®Google Scholar
• Tenney RM, Discher DE. Stem cells, microenvironment mechanics, and growth factor activation. Curr Opin Cell Biol 2009;21:630-5
   PubMed Web of Science ®Google Scholar
• Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol 2002;161:895-907
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72
   PubMed Web of Science ®Google Scholar
• Graf T, Enver T. Forcing cells to change lineages. Nature 2009;462:587-94
   PubMed Web of Science ®Google Scholar
• Vierbuchen T, Ostermeier A, Pang ZP, Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010;463:1035-41
   PubMed Web of Science ®Google Scholar
• Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009;10:116-25
   PubMed Web of Science ®Google Scholar
• Gelfand R, Vernet D, Kovanecz I, Specific molecular signatures characterize human tunica albuginea fibroblast, Peyronie's disease plaque myofibroblasts and corpora cavernosa smooth muscle cells and their response to a fibrotic stimulus. J Sex Med 2011;8(Suppl 1):6-7
   Google Scholar
• Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. J Sex Med 2009;6:1729-35
   PubMed Web of Science ®Google Scholar
• Karavitakis M, Komninos C, Simaioforidis V, The relationship between androgens, regulators of collagen metabolism, and Peyronie's disease: a case control study. J Sex Med 2010;7:4011-17
   PubMedGoogle Scholar